Form 4: MAIA Director Guerrero Granted Stock Options

MAIA Biotechnology Director Ramiro Guerrero was granted 20,459 stock options exercisable at $1.80 per share, vesting immediately.

Summary

• Ramiro Guerrero, a Director of MAIA Biotechnology, Inc. (MAIA), was granted 20,459 stock options.
• The options were granted on October 2, 2025, pursuant to MAIA Biotechnology, Inc.'s 2021 Equity Incentive Plan.
• Each option has an exercise price of $1.80 and represents the right to buy one share of common stock.
• The options vest 100% on the grant date, October 2, 2025, and are exercisable beginning as of that date.
• The expiration date for these stock options is October 2, 2035.
• Following this transaction, Ramiro Guerrero beneficially owns 20,459 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The grant of stock options to a director is a routine compensation event, generally viewed as neutral to slightly positive as it aligns management's interests with shareholder value creation.

Positives

• The grant of stock options aligns the director's financial interests with the long-term performance of MAIA Biotechnology, Inc. and its shareholders.
• The immediate 100% vesting of the options provides a clear and immediate incentive for the director.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance, but rather reports a past insider transaction.

Industry Context

Equity incentive plans and stock option grants are standard practices in the biotechnology industry to attract, retain, and motivate key personnel, including directors, by aligning their compensation with the company's long-term performance and shareholder interests.

Comparison to Industry Standards

• The grant of 20,459 stock options to a director is a common form of non-cash compensation within the biotechnology sector, comparable to practices at similar-sized development-stage biotech companies.
• Specific comparable companies or projects are not detailed in this filing, but such grants are typically benchmarked against peer group compensation data to ensure competitive and performance-aligned remuneration.

Stakeholder Impact

• Shareholders: Potential for increased alignment of the director's interests with shareholder value creation. Potential for future minor dilution if options are exercised, though this is a standard aspect of equity compensation plans.
• Director (Ramiro Guerrero): Receives equity-based compensation, providing a direct financial incentive tied to the company's stock performance.

Next Steps

• The director may choose to exercise the stock options at any time between the exercisable date (October 2, 2025) and the expiration date (October 2, 2035), subject to market conditions and personal financial planning.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director as part of an existing equity incentive plan. It does not provide new fundamental information or significant changes in company operations that would warrant an alteration to an investment thesis or recommendation.

Keywords

MAIA Biotechnology, MAIA, Stock Options, Form 4, Insider Transaction, Director Compensation, Equity Incentive Plan, Biotechnology